A major chunk of the population in UK suffers from skin diseases making it a desirable market for pharmaceutical companies. Eczema, psoriasis, and melanoma are some of the major dermatological disorders prevalent in the UK. Over the counter drugs hold a major share of the UK dermatology market.
The rising prevalence of mobility-impairing diseases and the increasing geriatric population requiring Long Term Care (LTC) in UK are the major market drivers for the growth of UK mobility aids market. Human Care and Drive Devilbiss Healthcare are some of the key players in the market.
An aging population and the increased prevalence of cardiovascular, neuromuscular, and musculoskeletal diseases in UK are most likely to propel the growth of the UK hand therapy market. Complex regional pain syndrome and fractures are major conditions that require hand therapy in UK.
UK physiotherapy market is at around $1.38 Bn in 2022 and is expected to grow to $1.87 Bn in 2030 with a CAGR of 3.85% for the year 2022-2030. The increasing geriatric population and high prevalence of musculoskeletal disorders are the major market drivers of UK physiotherapy market. The UK physiotherapy market is segmented by treatment and conditions.
The current demographics in UK make it an ideal market as the demand for anti-aging and overall skincare products is high thereby resulting in the growth of the UK anti-aging market during the forecast period. The market is segmented by product type, service type, route of administration and device type.
The UK patient support programs is expected to witness growth as the demand for more personalized medicine and care is increasing in the UK. Patients and Healthcare Services by Biogen and Together Enbrel Patient Support Program by Pfizer are some of the major pharma-sponsored PSPs in UK.